Clinical Trial

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2022-08-25; most recent amendment 2026-01-15.
Status change: Not Yet Recruiting → Recruiting 2022-09-20
Trial Details
NCT Number NCT05519449
Lead Sponsor Janux Therapeutics
Conditions Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer
Enrollment 272 participants
Start Date 2022-09-15
Primary Completion 2027-07 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-13